Michael Wang: Phenotype- and target-driven discovery are necessary for finding cures
Michael Wang shared on X a recent paper by Zhenyi Wang et al. titled “Innovating cancer drug discovery with refined phenotypic screens” published in Trends in Pharmacological Sciences.
Authors: Zhenyi Wang, Alzbeta Hulikova, Pawel Swietach
“Innovating Cancer Drug Discover with Refined Phenotypic Screens makes it clear that phenotype- and target-driven discovery are necessary for finding cures, and that technological advances have improved phenotypic screens’ discovery power.”
Source: Michael Wang/X
Michael Wang is a Professor in the Department of Lymphoma and Myeloma at MD Anderson Cancer Center, where he focuses on preclinical and clinical research. He has established the first human primary Mantle Cell Lymphoma (MCL) animal model, the MCL-SCID-hu mouse model, for studying the biology and treatment of MCL.
Dr. Wang has published over 150 peer-reviewed papers and has presented his work at national and international meetings. He is the current Director of the MCL Program of Excellence and Co-Director of Clinical Trials at MD Anderson. Additionally, he holds a joint appointment as a Professor in the Department of Stem Cell Transplantation at the same institution.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023